

AMENDMENTS TO LB390

(Amendments to Standing Committee amendments, AM1011)

Introduced by Morfeld, 46.

1           1. Insert the following new sections:

2           Sec. 4. Section 28-405, Revised Statutes Cumulative Supplement,  
3   2014, is amended to read:

4           28-405 The following are the schedules of controlled substances  
5   referred to in the Uniform Controlled Substances Act:

6           Schedule I

7           (a) Any of the following opiates, including their isomers, esters,  
8   ethers, salts, and salts of isomers, esters, and ethers, unless  
9   specifically excepted, whenever the existence of such isomers, esters,  
10   ethers, and salts is possible within the specific chemical designation:

11           (1) Acetylmethadol;

12           (2) Allylprodine;

13           (3) Alphacetylmethadol, except levo-alphacetylmethadol which is also  
14   known as levo-alpha-acetylmethadol, levomethadyl acetate, and LAAM;

15           (4) Alphameprodine;

16           (5) Alphamethadol;

17           (6) Benzethidine;

18           (7) Betacetylmethadol;

19           (8) Betameprodine;

20           (9) Betamethadol;

21           (10) Betaprodine;

22           (11) Clonitazene;

23           (12) Dextromoramide;

24           (13) Difenoxyin;

25           (14) Diampromide;

26           (15) Diethylthiambutene;

- 1 (16) Dimenoxadol;
- 2 (17) Dimepheptanol;
- 3 (18) Dimethylthiambutene;
- 4 (19) Dioxaphetyl butyrate;
- 5 (20) Dipipanone;
- 6 (21) Ethylmethylthiambutene;
- 7 (22) Etonitazene;
- 8 (23) Etoxeridine;
- 9 (24) Furethidine;
- 10 (25) Hydroxypethidine;
- 11 (26) Ketobemidone;
- 12 (27) Levomoramide;
- 13 (28) Levophenacylmorphane;
- 14 (29) Morpheridine;
- 15 (30) Noracymethadol;
- 16 (31) Norlevorphanol;
- 17 (32) Normethadone;
- 18 (33) Norpipanone;
- 19 (34) Phenadoxone;
- 20 (35) Phenampromide;
- 21 (36) Phenomorphan;
- 22 (37) Phenoperidine;
- 23 (38) Piritramide;
- 24 (39) Proheptazine;
- 25 (40) Properidine;
- 26 (41) Propiram;
- 27 (42) Racemoramide;
- 28 (43) Trimeperidine;
- 29 (44) Alpha-methylfentanyl, N-(1-(alpha-methyl-beta-phenyl)ethyl-4-
- 30 piperidyl) propionanilide, 1-(1-methyl-2-phenylethyl)-4-(N-propanilido)
- 31 piperidine;

- 1 (45) Tilidine;
- 2 (46) 3-Methylfentanyl, N-(3-methyl-1-(2-phenylethyl)-4-piperidyl)-N-  
3 phenylpropanamide, its optical and geometric isomers, salts, and salts of  
4 isomers;
- 5 (47) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP), its optical  
6 isomers, salts, and salts of isomers;
- 7 (48) PEPAP, 1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine, its  
8 optical isomers, salts, and salts of isomers;
- 9 (49) Acetyl-alpha-methylfentanyl, N-(1-(1-methyl-2-phenethyl)-4-  
10 piperidinyl)-N-phenylacetamide, its optical isomers, salts, and salts of  
11 isomers;
- 12 (50) Alpha-methylthiofentanyl, N-(1-methyl-2-(2-thienyl)ethyl-4-  
13 piperidinyl)-N-phenylpropanamide, its optical isomers, salts, and salts  
14 of isomers;
- 15 (51) Benzylfentanyl, N-(1-benzyl-4-piperidyl)-N-phenylpropanamide,  
16 its optical isomers, salts, and salts of isomers;
- 17 (52) Beta-hydroxyfentanyl, N-(1-(2-hydroxy-2-phenethyl)-4-  
18 piperidinyl)-N-phenylpropanamide, its optical isomers, salts, and salts  
19 of isomers;
- 20 (53) Beta-hydroxy-3-methylfentanyl, (other name: N-(1-(2-hydroxy-2-  
21 phenethyl)-3-methyl-4-piperidinyl)-N-phenylpropanamide), its optical and  
22 geometric isomers, salts, and salts of isomers;
- 23 (54) 3-methylthiofentanyl, N-(3-methyl-1-(2-thienyl)ethyl-4-  
24 piperidinyl)-N-phenylpropanamide, its optical and geometric isomers,  
25 salts, and salts of isomers;
- 26 (55) N-(1-(2-thienyl)methyl-4-piperidyl)-N-phenylpropanamide  
27 (thenylfentanyl), its optical isomers, salts, and salts of isomers;
- 28 (56) Thiofentanyl, N-phenyl-N-(1-(2-thienyl)ethyl-4-piperidinyl)-  
29 propanamide, its optical isomers, salts, and salts of isomers; and
- 30 (57) Para-fluorofentanyl, N-(4-fluorophenyl)-N-(1-(2-phenethyl)-4-  
31 piperidinyl)propanamide, its optical isomers, salts, and salts of

1 isomers.

2 (b) Any of the following opium derivatives, their salts, isomers,  
3 and salts of isomers, unless specifically excepted, whenever the  
4 existence of such salts, isomers, and salts of isomers is possible within  
5 the specific chemical designation:

- 6 (1) Acetorphine;
- 7 (2) Acetyldihydrocodeine;
- 8 (3) Benzylmorphine;
- 9 (4) Codeine methylbromide;
- 10 (5) Codeine-N-Oxide;
- 11 (6) Cyprenorphine;
- 12 (7) Desomorphine;
- 13 (8) Dihydromorphine;
- 14 (9) Drotebanol;
- 15 (10) Etorphine, except hydrochloride salt;
- 16 (11) Heroin;
- 17 (12) Hydromorphanol;
- 18 (13) Methyldesorphine;
- 19 (14) Methyldihydromorphine;
- 20 (15) Morphine methylbromide;
- 21 (16) Morphine methylsulfonate;
- 22 (17) Morphine-N-Oxide;
- 23 (18) Myrophine;
- 24 (19) Nicocodeine;
- 25 (20) Nicomorphine;
- 26 (21) Normorphine;
- 27 (22) Pholcodine; and
- 28 (23) Thebacon.

29 (c) Any material, compound, mixture, or preparation which contains  
30 any quantity of the following hallucinogenic substances, their salts,  
31 isomers, and salts of isomers, unless specifically excepted, whenever the

1 existence of such salts, isomers, and salts of isomers is possible within  
2 the specific chemical designation, and, for purposes of this subdivision  
3 only, isomer shall include the optical, position, and geometric isomers:

4 (1) Bufotenine. Trade and other names shall include, but are not  
5 limited to: 3-(beta-Dimethylaminoethyl)-5-hydroxyindole; 3-(2-  
6 dimethylaminoethyl)-5-indolol; N,N-dimethylserotonin; 5-hydroxy-N,N-  
7 dimethyltryptamine; and mappine;

8 (2) 4-bromo-2,5-dimethoxyamphetamine. Trade and other names shall  
9 include, but are not limited to: 4-bromo-2,5-dimethoxy-alpha-  
10 methylphenethylamine; and 4-bromo-2,5-DMA;

11 (3) 4-methoxyamphetamine. Trade and other names shall include, but  
12 are not limited to: 4-methoxy-alpha-methylphenethylamine; and  
13 paramethoxyamphetamine, PMA;

14 (4) 4-methyl-2,5-dimethoxyamphetamine. Trade and other names shall  
15 include, but are not limited to: 4-methyl-2,5-dimethoxy-alpha-  
16 methylphenethylamine; DOM; and STP;

17 (5) Ibogaine. Trade and other names shall include, but are not  
18 limited to: 7-Ethyl-6,6beta,7,8,9,10,12,13-octahydro-2-methoxy-6,9-  
19 methano-5H-pyrido (1',2':1,2) azepino (5,4-b) indole; and Tabernanthe  
20 iboga;

21 (6) Lysergic acid diethylamide;

22 (7) Marijuana;

23 (8) Mescaline;

24 (9) Peyote. Peyote shall mean all parts of the plant presently  
25 classified botanically as *Lophophora williamsii* Lemaire, whether growing  
26 or not, the seeds thereof, any extract from any part of such plant, and  
27 every compound, manufacture, salts, derivative, mixture, or preparation  
28 of such plant or its seeds or extracts;

29 (10) Psilocybin;

30 (11) Psilocyn;

31 (12) Tetrahydrocannabinols, including, but not limited to, synthetic

1 equivalents of the substances contained in the plant or in the resinous  
2 extractives of cannabis, sp. or synthetic substances, derivatives, and  
3 their isomers with similar chemical structure and pharmacological  
4 activity such as the following: Delta 1 cis or trans tetrahydrocannabinol  
5 and their optical isomers, excluding dronabinol in sesame oil and  
6 encapsulated in a soft gelatin capsule in a drug product approved by the  
7 federal Food and Drug Administration; Delta 6 cis or trans  
8 tetrahydrocannabinol and their optical isomers; and Delta 3,4 cis or  
9 trans tetrahydrocannabinol and its optical isomers. Since nomenclature of  
10 these substances is not internationally standardized, compounds of these  
11 structures shall be included regardless of the numerical designation of  
12 atomic positions covered;

13 (13) N-ethyl-3-piperidyl benzilate;

14 (14) N-methyl-3-piperidyl benzilate;

15 (15) Thiophene analog of phencyclidine. Trade and other names shall  
16 include, but are not limited to: 1-(1-(2-thienyl)-cyclohexyl)-piperidine;  
17 2-thienyl analog of phencyclidine; TCP; and TCP;

18 (16) Hashish or concentrated cannabis;

19 (17) Parahexyl. Trade and other names shall include, but are not  
20 limited to: 3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-  
21 dibenzo(b,d)pyran; and Synhexyl;

22 (18) Ethylamine analog of phencyclidine. Trade and other names shall  
23 include, but are not limited to: N-ethyl-1-phenylcyclohexylamine; (1-  
24 phenylcyclohexyl)ethylamine; N-(1-phenylcyclohexyl)ethylamine;  
25 cyclohexamine; and PCE;

26 (19) Pyrrolidine analog of phencyclidine. Trade and other names  
27 shall include, but are not limited to: 1-(1-phenylcyclohexyl)-  
28 pyrrolidine; PCPy; and PHP;

29 (20) Alpha-ethyltryptamine. Some trade or other names: etryptamine;  
30 Monase; alpha-ethyl-1H-indole-3-ethanamine; 3-(2-aminobutyl) indole;  
31 alpha-ET; and AET;

1 (21) 2,5-dimethoxy-4-ethylamphet-amine; and DOET;

2 (22) 1-(1-(2-thienyl)cyclohexyl)pyrrolidine; and TCPy;

3 (23) Alpha-methyltryptamine, which is also known as AMT;

4 (24) Salvia divinorum or Salvinorin A. Salvia divinorum or  
5 Salvinorin A includes all parts of the plant presently classified  
6 botanically as Salvia divinorum, whether growing or not, the seeds  
7 thereof, any extract from any part of such plant, and every compound,  
8 manufacture, derivative, mixture, or preparation of such plant, its  
9 seeds, or its extracts, including salts, isomers, and salts of isomers  
10 whenever the existence of such salts, isomers, and salts of isomers is  
11 possible within the specific chemical designation;

12 (25) Any material, compound, mixture, or preparation containing any  
13 quantity of synthetically produced cannabinoids as listed in subdivisions  
14 (A) through (L M) of this subdivision, including their salts, isomers,  
15 salts of isomers, and nitrogen, oxygen, or sulfur-heterocyclic nitrogen-  
16 ~~heterocyclic~~ analogs, unless specifically excepted elsewhere in this  
17 section. Since nomenclature of these synthetically produced cannabinoids  
18 is not internationally standardized and may continually evolve, these  
19 structures or compounds of these structures shall be included under this  
20 subdivision, regardless of their specific numerical designation of atomic  
21 positions covered, so long as it can be determined through a recognized  
22 method of scientific testing or analysis that the substance contains  
23 properties that fit within one or more of the following categories:

24 (A) Tetrahydrocannabinols: Meaning tetrahydrocannabinols naturally  
25 contained in a plant of the genus cannabis (cannabis plant), as well as  
26 synthetic equivalents of the substances contained in the plant, or in the  
27 resinous extractives of cannabis, sp. and/or synthetic substances,  
28 derivatives, and their isomers with similar chemical structure and  
29 pharmacological activity such as the following: Delta 1 cis or trans  
30 tetrahydrocannabinol, and their optical isomers; Delta 6 cis or trans  
31 tetrahydrocannabinol, and their optical isomers; Delta 3,4 cis or trans

1 tetrahydrocannabinol, and its optical isomers;

2 (B) Naphthoylindoles: Any compound containing a 3-(1-  
3 naphthoyl)indole structure with substitution at the nitrogen atom of the  
4 indole ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl,  
5 cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group,  
6 cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-  
7 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or  
8 tetrahydropyranylmethyl group, whether or not further substituted in or  
9 on any of the listed ring systems the indole ring to any extent and  
10 whether or not substituted in the naphthyl ring to any extent;

11 (C) Naphthylmethylinindoles: Any compound containing a 1 H-indol-3-yl-  
12 (1-naphthyl)methane structure with substitution at the nitrogen atom of  
13 the indole ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl,  
14 cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group,  
15 cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-  
16 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or  
17 tetrahydropyranylmethyl group, whether or not further substituted in or  
18 on any of the listed ring systems the indole ring to any extent and  
19 whether or not substituted in the naphthyl ring to any extent;

20 (D) Naphthoylpyrroles: Any compound containing a 3-(1-  
21 naphthoyl)pyrrole structure with substitution at the nitrogen atom of the  
22 pyrrole ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl,  
23 cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group,  
24 cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-  
25 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or  
26 tetrahydropyranylmethyl group, whether or not further substituted in or  
27 on any of the listed ring systems the pyrrole ring to any extent and  
28 whether or not substituted in the naphthyl ring to any extent;

29 (E) Naphthylideneindenes: Any compound containing a  
30 naphthylideneindene structure with substitution at the 3-position of the  
31 indene ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl,



1 cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group,  
2 cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-  
3 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or  
4 tetrahydropyranylmethyl group, whether or not further substituted in or  
5 on any of the listed ring systems ~~the indene ring to any extent and~~  
6 ~~whether or not substituted in the naphthyl ring to any extent;~~

7 (F) Phenylacetylindoles: Any compound containing a 3-  
8 phenylacetylindole structure with substitution at the nitrogen atom of  
9 the indole ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl,  
10 cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group,  
11 cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-  
12 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or  
13 tetrahydropyranylmethyl group, whether or not further substituted in or  
14 on any of the listed ring systems ~~the indole ring to any extent and~~  
15 ~~whether or not substituted in the phenyl ring to any extent;~~

16 (G) Cyclohexylphenols: Any compound containing a 2-(3-  
17 hydroxycyclohexyl)phenol structure with substitution at the 5-position of  
18 the phenolic ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl,  
19 cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group,  
20 cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-  
21 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or  
22 tetrahydropyranylmethyl group, whether or not substituted in or on any of  
23 the listed ring systems ~~the cyclohexyl ring to any extent;~~

24 (H) Benzoylindoles: Any compound containing a 3-(benzoyl)indole  
25 structure with substitution at the nitrogen atom of the indole ring by an  
26 alkyl, haloalkyl, alkenyl, halobenzyl, benzyl, cycloalkylmethyl,  
27 cycloalkylethyl, 2-(4-morpholinyl)ethyl group, cyanoalkyl, 1-(N-methyl-2-  
28 piperidinyl)methyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-  
29 morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not  
30 further substituted in or on any of the listed ring systems ~~the indole~~  
31 ~~ring to any extent and whether or not substituted in the phenyl ring to~~

1 any extent;

2 (I) Adamantoylindoles: Any compound containing a 3-adamantoylindole  
3 structure with substitution at the nitrogen atom of the indole ring by an  
4 alkyl, haloalkyl, cyanoalkyl, alkenyl, halobenzyl, benzyl,  
5 cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-  
6 (4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-  
7 morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not  
8 further substituted in or on any of the listed ring systems ~~the indole~~  
9 ~~ring to any extent and whether or not substituted in the adamantyl ring~~  
10 to any extent;

11 (J) Tetramethylcyclopropanoylindoles: Any compound containing a 3-  
12 tetramethylcyclopropanoylindole structure with substitution at the  
13 nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl,  
14 alkenyl, halobenzyl, benzyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-  
15 methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-  
16 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or  
17 tetrahydropyranylmethyl group, whether or not further substituted in or  
18 on any of the listed ring systems ~~the indole ring to any extent and~~  
19 ~~whether or not substituted in the tetramethylcyclopropyl ring to any~~  
20 extent;

21 (K) Indole carboxamides: Any compound containing a 1-indole-3-  
22 carboxamide structure with substitution at the nitrogen atom of the  
23 indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, halobenzyl,  
24 benzyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-  
25 piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-  
26 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or  
27 tetrahydropyranylmethyl group, substitution at the carboxamide group by  
28 an alkyl, methoxy, benzyl, propionaldehyde, adamantyl, 1-naphthyl,  
29 phenyl, or aminoalkyl group, or quinolinyl group, whether or not  
30 further substituted in or on any of the listed ring systems to any extent  
31 or to the adamantyl, 1-naphthyl, phenyl, aminoalkyl, benzyl, or

1 propionaldehyde groups to any extent;

2 (L) Indole carboxylates: Any compound containing a 1-indole-3-  
3 carboxylate structure with substitution at the nitrogen atom of the  
4 indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, halobenzyl,  
5 benzyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-  
6 piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-  
7 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or  
8 tetrahydropyranylmethyl group, substitution at the carboxylate group by  
9 an alkyl, methoxy, benzyl, propionaldehyde, adamantyl, 1-naphthyl,  
10 phenyl, aminooxoalkyl group, or quinolinyl group, whether or not further  
11 substituted in or on any of the listed ring systems to any extent or to  
12 the adamantyl, 1-naphthyl, phenyl, aminooxoalkyl, benzyl, or  
13 propionaldehyde groups to any extent; and

14 (M) Any nonnaturally occurring substance, chemical compound,  
15 mixture, or preparation, not specifically listed elsewhere in these  
16 schedules and which is not approved for human consumption by the federal  
17 Food and Drug Administration, containing or constituting a cannabinoid  
18 receptor agonist as defined in section 28-401;

19 (26) Any material, compound, mixture, or preparation containing any  
20 quantity of a substituted phenethylamine as listed in subdivisions (A)  
21 through (C) of this subdivision, unless specifically excepted, listed in  
22 another schedule, or specifically named in this schedule, that is  
23 structurally derived from phenylethan-2-amine by substitution on the  
24 phenyl ring with a fused methylenedioxy ring, fused furan ring, or a  
25 fused tetrahydrofuran ring; by substitution with two alkoxy groups; by  
26 substitution with one alkoxy and either one fused furan, tetrahydrofuran,  
27 or tetrahydropyran ring system; or by substitution with two fused ring  
28 systems from any combination of the furan, tetrahydrofuran, or  
29 tetrahydropyran ring systems, whether or not the compound is further  
30 modified in any of the following ways:

31 (A) Substitution of the phenyl ring by any halo, hydroxyl, alkyl,

1 trifluoromethyl, alkoxy, or alkylthio groups; (B) substitution at the 2-  
2 position by any alkyl groups; or (C) substitution at the 2-amino nitrogen  
3 atom with alkyl, dialkyl, benzyl, hydroxybenzyl or methoxybenzyl groups,  
4 and including, but not limited to:

5 (i) 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine, which is also known  
6 as 2C-C or 2,5-Dimethoxy-4-chlorophenethylamine;

7 (ii) 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine, which is also known  
8 as 2C-D or 2,5-Dimethoxy-4-methylphenethylamine;

9 (iii) 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine, which is also known  
10 as 2C-E or 2,5-Dimethoxy-4-ethylphenethylamine;

11 (iv) 2-(2,5-Dimethoxyphenyl)ethanamine, which is also known as 2C-H  
12 or 2,5-Dimethoxyphenethylamine;

13 (v) 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine, which is also known as  
14 2C-I or 2,5-Dimethoxy-4-iodophenethylamine;

15 (vi) 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine, which is also known  
16 as 2C-N or 2,5-Dimethoxy-4-nitrophenethylamine;

17 (vii) 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine, which is also  
18 known as 2C-P or 2,5-Dimethoxy-4-propylphenethylamine;

19 (viii) 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine, which is  
20 also known as 2C-T-2 or 2,5-Dimethoxy-4-ethylthiophenethylamine;

21 (ix) 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine, which is  
22 also known as 2C-T-4 or 2,5-Dimethoxy-4-isopropylthiophenethylamine;

23 (x) 2-(4-bromo-2,5-dimethoxyphenyl)ethanamine, which is also known  
24 as 2C-B or 2,5-Dimethoxy-4-bromophenethylamine;

25 (xi) 2-(2,5-dimethoxy-4-(methylthio)phenyl)ethanamine, which is also  
26 known as 2C-T or 4-methylthio-2,5-dimethoxyphenethylamine;

27 (xii) 1-(2,5-dimethoxy-4-iodophenyl)-propan-2-amine, which is also  
28 known as DOI or 2,5-Dimethoxy-4-iodoamphetamine;

29 (xiii) 1-(4-Bromo-2,5-dimethoxyphenyl)-2-aminopropane, which is also  
30 known as DOB or 2,5-Dimethoxy-4-bromoamphetamine;

31 (xiv) 1-(4-chloro-2,5-dimethoxy-phenyl)propan-2-amine, which is also

- 1 known as DOC or 2,5-Dimethoxy-4-chloroamphetamine;
- 2 (xv) 2-(4-bromo-2,5-dimethoxyphenyl)-N-[(2-  
3 methoxyphenyl)methyl]ethanamine, which is also known as 2C-B-NBOMe; 25B-  
4 NBOMe or 2,5-Dimethoxy-4-bromo-N-(2-methoxybenzyl)phenethylamine;
- 5 (xvi) 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-  
6 methoxyphenyl)methyl]ethanamine, which is also known as 2C-I-NBOMe; 25I-  
7 NBOMe or 2,5-Dimethoxy-4-iodo-N-(2-methoxybenzyl)phenethylamine;
- 8 (xvii) N-(2-Methoxybenzyl)-2-(3,4,5-trimethoxyphenyl)ethanamine,  
9 which is also known as Mescaline-NBOMe or 3,4,5-trimethoxy-N-(2-  
10 methoxybenzyl)phenethylamine;
- 11 (xviii) 2-(4-chloro-2,5-dimethoxyphenyl)-N-[(2-  
12 methoxyphenyl)methyl]ethanamine, which is also known as 2C-C-NBOMe; or  
13 25C-NBOMe or 2,5-Dimethoxy-4-chloro-N-(2-methoxybenzyl)phenethylamine;
- 14 (xix) 2-(7-Bromo-5-methoxy-2,3-dihydro-1-benzofuran-4-yl)ethanamine,  
15 which is also known as 2CB-5-hemiFLY;
- 16 (xx) 2-(8-bromo-2,3,6,7-tetrahydrofuro [2,3-f][1]benzofuran-4-  
17 yl)ethanamine, which is also known as 2C-B-FLY;
- 18 (xxi) 2-(10-Bromo-2,3,4,7,8,9-hexahydropyrano[2,3-g]chromen-5-  
19 yl)ethanamine, which is also known as 2C-B-butterFLY;
- 20 (xxii) N-(2-Methoxybenzyl)-1-(8-bromo-2,3,6,7- tetrahydrobenzo[1,2-  
21 b:4,5-b']difuran-4-yl)-2-aminoethane, which is also known as 2C-B-FLY-  
22 NBOMe;
- 23 (xxiii) 1-(4-Bromofuro[2,3-f][1]benzofuran-8-yl)propan-2-amine,  
24 which is also known as bromo-benzodifuranylisopropylamine or bromo-  
25 dragonFLY;
- 26 (xxiv) N-(2-Hydroxybenzyl)-4-iodo-2,5-dimethoxyphenethylamine, which  
27 is also known as 2C-INBOH or 25I-NBOH;
- 28 (xxv) 5-(2-Aminopropyl)benzofuran, which is also known as 5-APB;
- 29 (xxvi) 6-(2-Aminopropyl)benzofuran, which is also known as 6-APB;
- 30 (xxvii) 5-(2-Aminopropyl)-2,3-dihydrobenzofuran, which is also known  
31 as 5-APDB;

1 (xxviii) 6-(2-Aminopropyl)-2,3-dihydrobenzofuran, which is also  
2 known as 6-APDB;

3 (xxix) 2,5-dimethoxy-amphetamine, which is also known as 2, 5-  
4 dimethoxy- $\alpha$ -methylphenethylamine; 2, 5-DMA;

5 (xxx) 2,5-dimethoxy-4-ethylamphetamine, which is also known as DOET;

6 (xxxi) 2,5-dimethoxy-4-(n)-propylthiophenethylamine, which is also  
7 known as 2C-T-7;

8 (xxxii) 5-methoxy-3,4-methylenedioxy-amphetamine;

9 (xxxiii) 4-methyl-2,5-dimethoxy-amphetamine, which is also known as  
10 4-methyl-2,5-dimethoxy- $\alpha$ -methylphenethylamine; DOM and STP;

11 (xxxiv) 3,4-methylenedioxy amphetamine, which is also known as MDA;

12 (xxxv) 3,4-methylenedioxymethamphetamine, which is also known as  
13 MDMA;

14 (xxxvi) 3,4-methylenedioxy-N-ethylamphetamine, which is also known  
15 as N-ethyl- $\alpha$ -methyl-3,4(methylenedioxy)phenethylamine, MDE, MDEA; and

16 (xxxvii) 3,4,5-trimethoxy amphetamine;

17 (27) Any material, compound, mixture, or preparation containing any  
18 quantity of a substituted tryptamine unless specifically excepted, listed  
19 in another schedule, or specifically named in this schedule, that is  
20 structurally derived from 2-(1H-indol-3-yl)ethanamine, which is also  
21 known as tryptamine, by mono- or di-substitution of the amine nitrogen  
22 with alkyl or alkenyl groups or by inclusion of the amino nitrogen atom  
23 in a cyclic structure whether or not the compound is further substituted  
24 at the alpha position with an alkyl group or whether or not further  
25 substituted on the indole ring to any extent with any alkyl, alkoxy,  
26 halo, hydroxyl, or acetoxy groups, and including, but not limited to:

27 (A) 5-methoxy-N,N-diallyltryptamine, which is also known as 5-MeO-  
28 DALT;

29 (B) 4-acetoxy-N,N-dimethyltryptamine, which is also known as 4-AcO-  
30 DMT or OAcetylpsilocin;

31 (C) 4-hydroxy-N-methyl-N-ethyltryptamine, which is also known as 4-

1 HO-MET;

2 (D) 4-hydroxy-N,N-diisopropyltryptamine, which is also known as 4-  
3 HO-DIPT;

4 (E) 5-methoxy-N-methyl-N-isopropyltryptamine, which is also known as  
5 5-MeOMiPT;

6 (F) 5-Methoxy-N,N-Dimethyltryptamine, which is also known as 5-MeO-  
7 DMT;

8 (G) 5-methoxy-N,N-diisopropyltryptamine, which is also known as 5-  
9 MeO-DiPT;

10 (H) Diethyltryptamine, which is also known as N,N-Diethyltryptamine,  
11 DET; and

12 (I) Dimethyltryptamine, which is also known as DMT; and

13 (28)(A) Any substance containing any quantity of the following  
14 materials, compounds, mixtures, or structures:

15 (i) 3,4-methylenedioxymethcathinone, or bk-MDMA, or methylone;

16 (ii) 3,4-methylenedioxypyrovalerone, or MDPV;

17 (iii) 4-methylmethcathinone, or 4-MMC, or mephedrone;

18 (iv) 4-methoxymethcathinone, or bk-PMMA, or PMMC, or methedrone;

19 (v) Fluoromethcathinone, or FMC;

20 (vi) Naphthylpyrovalerone, or naphyrone; or

21 (vii) Beta-keto-N-methylbenzodioxolylpropylamine or bk-MBDB or  
22 butylone; or

23 (B) Unless listed in another schedule, any substance which contains  
24 any quantity of any material, compound, mixture, or structure, other than  
25 bupropion ~~buproprion~~, that is structurally derived by any means from 2-  
26 aminopropan-1-one by substitution at the 1-position with either phenyl,  
27 naphthyl, or thiophene ring systems, whether or not the compound is  
28 further modified in any of the following ways:

29 (i) Substitution in the ring system to any extent with alkyl,  
30 alkoxy, alkylenedioxy, haloalkyl, hydroxyl, or halide substituents,  
31 whether or not further substituted in the ring system by one or more

1 other univalent substituents;

2 (ii) Substitution at the 3-position with an acyclic alkyl  
3 substituent; or

4 (iii) Substitution at the 2-amino nitrogen atom with alkyl or  
5 dialkyl groups, or by inclusion of the 2-amino nitrogen atom in a cyclic  
6 structure.

7 (d) Unless specifically excepted or unless listed in another  
8 schedule, any material, compound, mixture, or preparation which contains  
9 any quantity of the following substances having a depressant effect on  
10 the central nervous system, including its salts, isomers, and salts of  
11 isomers whenever the existence of such salts, isomers, and salts of  
12 isomers is possible within the specific chemical designation:

13 (1) Mecloqualone;

14 (2) Methaqualone; and

15 (3) Gamma-Hydroxybutyric Acid. Some other names include: GHB; Gamma-  
16 hydroxybutyrate; 4-Hydroxybutyrate; 4-Hydroxybutanoic Acid; Sodium  
17 Oxybate; and Sodium Oxybutyrate.

18 (e) Unless specifically excepted or unless listed in another  
19 schedule, any material, compound, mixture, or preparation which contains  
20 any quantity of the following substances having a stimulant effect on the  
21 central nervous system, including its salts, isomers, and salts of  
22 isomers:

23 (1) Fenethylamine;

24 (2) N-ethylamphetamine;

25 (3) Aminorex; aminoxaphen; 2-amino-5-phenyl-2-oxazoline; or 4,5-  
26 dihydro-5-phenyl-2-oxazolamine;

27 (4) Cathinone; 2-amino-1-phenyl-1-propanone; alpha-  
28 aminopropiophenone; 2-aminopropiophenone; and norephedrone;

29 (5) Methcathinone, its salts, optical isomers, and salts of optical  
30 isomers. Some other names: 2-(methylamino)-propionophenone; alpha-  
31 (methylamino)propionophenone; 2-(methylamino)-1-phenylpropan-1-one; alpha-



- 1 N-methylaminopropiophenone; methylcathinone; monomethylpropion;  
2 ephedrone; N-methylcathinone; AL-464; AL-422; AL-463; and UR1432;  
3 (6) (+/-)cis-4-methylaminorex; and (+/-)cis-4,5-dihydro-4-methyl-5-  
4 phenyl-2-oxazolamine;  
5 (7) N,N-dimethylamphetamine; N,N-alpha-trimethyl-benzeneethanamine;  
6 and N,N-alpha-trimethylphenethylamine; and  
7 (8) Benzylpiperazine, 1-benzylpiperazine.  
8 (f) Any controlled substance analogue to the extent intended for  
9 human consumption.

10 Schedule II

11 (a) Any of the following substances except those narcotic drugs  
12 listed in other schedules whether produced directly or indirectly by  
13 extraction from substances of vegetable origin, independently by means of  
14 chemical synthesis, or by combination of extraction and chemical  
15 synthesis:

16 (1) Opium and opiate, and any salt, compound, derivative, or  
17 preparation of opium or opiate, excluding apomorphine, buprenorphine,  
18 thebaine-derived butorphanol, dextrorphan, nalbuphine, nalmeffene,  
19 naloxone, and naltrexone and their salts, but including the following:

- 20 (A) Raw opium;  
21 (B) Opium extracts;  
22 (C) Opium fluid;  
23 (D) Powdered opium;  
24 (E) Granulated opium;  
25 (F) Tincture of opium;  
26 (G) Codeine;  
27 (H) Ethylmorphine;  
28 (I) Etorphine hydrochloride;  
29 (J) Hydrocodone;  
30 (K) Hydromorphone;  
31 (L) Metopon;

- 1 (M) Morphine;
- 2 (N) Oxycodone;
- 3 (O) Oxymorphone;
- 4 (P) Oripavine;
- 5 (Q) Thebaine; and
- 6 (R) Dihydroetorphine;
- 7 (2) Any salt, compound, derivative, or preparation thereof which is
- 8 chemically equivalent to or identical with any of the substances referred
- 9 to in subdivision (1) of this subdivision, except that these substances
- 10 shall not include the isoquinoline alkaloids of opium;
- 11 (3) Opium poppy and poppy straw;
- 12 (4) Coca leaves and any salt, compound, derivative, or preparation
- 13 of coca leaves, and any salt, compound, derivative, or preparation
- 14 thereof which is chemically equivalent to or identical with any of these
- 15 substances, including cocaine and its salts, optical isomers, and salts
- 16 of optical isomers, except that the substances shall not include
- 17 decocainized coca leaves or extractions which do not contain cocaine or
- 18 ecgonine; and
- 19 (5) Concentrate of poppy straw, the crude extract of poppy straw in
- 20 either liquid, solid, or powder form which contains the phenanthrene
- 21 alkaloids of the opium poppy.
- 22 (b) Unless specifically excepted or unless in another schedule any
- 23 of the following opiates, including their isomers, esters, ethers, salts,
- 24 and salts of their isomers, esters, and ethers whenever the existence of
- 25 such isomers, esters, ethers, and salts is possible within the specific
- 26 chemical designation, dextrorphan excepted:
- 27 (1) Alphaprodine;
- 28 (2) Anileridine;
- 29 (3) Bezitramide;
- 30 (4) Diphenoxylate;
- 31 (5) Fentanyl;

- 1 (6) Isomethadone;
- 2 (7) Levomethorphan;
- 3 (8) Levorphanol;
- 4 (9) Metazocine;
- 5 (10) Methadone;
- 6 (11) Methadone-intermediate, 4-cyano-2-dimethylamino-4,4-diphenyl
- 7 butane;
- 8 (12) Moramide-intermediate, 2-methyl-3-morpholino-1,1-
- 9 diphenylpropane-carboxylic acid;
- 10 (13) Pethidine or meperidine;
- 11 (14) Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine;
- 12 (15) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-
- 13 carboxylate;
- 14 (16) Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-
- 15 carboxylic acid;
- 16 (17) Phenazocine;
- 17 (18) Piminodine;
- 18 (19) Racemethorphan;
- 19 (20) Racemorphan;
- 20 (21) Dihydrocodeine;
- 21 (22) Bulk Propoxyphene in nondosage forms;
- 22 (23) Sufentanil;
- 23 (24) Alfentanil;
- 24 (25) Levo-alphaacetylmethadol which is also known as levo-alpha-
- 25 acetylmethadol, levomethadyl acetate, and LAAM;
- 26 (26) Carfentanil;
- 27 (27) Remifentanil; and
- 28 (28) Tapentadol.
- 29 (c) Any material, compound, mixture, or preparation which contains
- 30 any quantity of the following substances having a potential for abuse
- 31 associated with a stimulant effect on the central nervous system:

1 (1) Amphetamine, its salts, optical isomers, and salts of its  
2 optical isomers;

3 (2) Phenmetrazine and its salts;

4 (3) Methamphetamine, its salts, isomers, and salts of its isomers;

5 and

6 (4) Methylphenidate; and -

7 (5) Lisdexamfetamine, its salts, isomers, and salts of its isomers.

8 (d) Any material, compound, mixture, or preparation which contains  
9 any quantity of the following substances having a potential for abuse  
10 associated with a depressant effect on the central nervous system,  
11 including their salts, isomers, and salts of isomers whenever the  
12 existence of such salts, isomers, and salts of isomers is possible within  
13 the specific chemical designations:

14 (1) Amobarbital;

15 (2) Secobarbital;

16 (3) Pentobarbital;

17 (4) Phencyclidine; and

18 (5) Glutethimide.

19 (e) Hallucinogenic substances known as:

20 (1) Nabilone. Another name for nabilone: (+/-)-trans-3-(1,1-  
21 dimethylheptyl)- 6,6a,7,8,10,10a-Hexahydro-1-hydroxy-6,6-dimethyl-9H-  
22 dibenzo(b,d)pyran-9-one.

23 (f) Unless specifically excepted or unless listed in another  
24 schedule, any material, compound, mixture, or preparation which contains  
25 any quantity of the following substances:

26 (1) Immediate precursor to amphetamine and methamphetamine:  
27 Phenylacetone. Trade and other names shall include, but are not limited  
28 to: Phenyl-2-propanone; P2P; benzyl methyl ketone; and methyl benzyl  
29 ketone; or

30 (2) Immediate precursors to phencyclidine, PCP:

31 (A) 1-phenylcyclohexylamine; ~~or~~

1 (B) 1-piperidinocyclohexanecarbonitrile, PCC; or -

2 (3) Immediate precursor to fentanyl; 4-anilino-N-phenethyl-4-  
3 piperidine (ANNPP).

4 Schedule III

5 (a) Any material, compound, mixture, or preparation which contains  
6 any quantity of the following substances having a potential for abuse  
7 associated with a stimulant effect on the central nervous system,  
8 including their salts, isomers, whether optical, position, or geometric,  
9 and salts of such isomers whenever the existence of such salts, isomers,  
10 and salts of isomers is possible within the specific chemical  
11 designation:

12 (1) Benzphetamine;

13 (2) Chlorphentermine;

14 (3) Clortermine; and

15 (4) Phendimetrazine.

16 (b) Any material, compound, mixture, or preparation which contains  
17 any quantity of the following substances having a potential for abuse  
18 associated with a depressant effect on the central nervous system:

19 (1) Any substance which contains any quantity of a derivative of  
20 barbituric acid or any salt of a derivative of barbituric acid, except  
21 those substances which are specifically listed in other schedules of this  
22 section;

23 (2) Chlorhexadol;

24 (3) Embutramide;

25 (4 ~~3~~) Lysergic acid;

26 (5 ~~4~~) Lysergic acid amide;

27 (6 ~~5~~) Methyprylon;

28 (7) Perampanel;

29 (8 ~~6~~) Sulfondiethylmethane;

30 (9 ~~7~~) Sulfonethylmethane;

31 (10 ~~8~~) Sulfonmethane;

1 (11 9) Nalorphine;

2 (12 10) Any compound, mixture, or preparation containing  
3 amobarbital, secobarbital, pentobarbital, or any salt thereof and one or  
4 more other active medicinal ingredients which are not listed in any  
5 schedule;

6 (13 11) Any suppository dosage form containing amobarbital,  
7 secobarbital, pentobarbital, or any salt of any of these drugs and  
8 approved by the federal Food and Drug Administration for marketing only  
9 as a suppository;

10 (14 12) Any drug product containing gamma-hydroxybutyric acid,  
11 including its salts, isomers, and salts of isomers, for which an  
12 application is approved under section 505 of the Federal Food, Drug, and  
13 Cosmetic Act, 21 U.S.C. 355, as such section existed on January 1, 2014;

14 (15 13) Ketamine, its salts, isomers, and salts of isomers. Some  
15 other names for ketamine: (+/-)-2-(2-chlorophenyl)-2-(methylamino)-  
16 cyclohexanone; and

17 (16 14) Tiletamine and zolazepam or any salt thereof. Trade or other  
18 names for a tiletamine-zolazepam combination product shall include, but  
19 are not limited to: telazol. Trade or other names for tiletamine shall  
20 include, but are not limited to: 2-(ethylamino)-2-(2-thienyl)-  
21 cyclohexanone. Trade or other names for zolazepam shall include, but are  
22 not limited to: 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-  
23 (3,4-e) (1,4)-diazepin-7(1H)-one, and flupyrazapon.

24 (c) Unless specifically excepted or unless listed in another  
25 schedule:

26 (1) Any material, compound, mixture, or preparation containing  
27 limited quantities of any of the following narcotic drugs, or any salts  
28 calculated as the free anhydrous base or alkaloid, in limited quantities  
29 as set forth below:

30 (A) Not more than one and eight-tenths grams of codeine per one  
31 hundred milliliters or not more than ninety milligrams per dosage unit,

1 with an equal or greater quantity of an isoquinoline alkaloid of opium;

2 (B) Not more than one and eight-tenths grams of codeine per one  
3 hundred milliliters or not more than ninety milligrams per dosage unit,  
4 with one or more active, nonnarcotic ingredients in recognized  
5 therapeutic amounts;

6 ~~(C) Not more than three hundred milligrams of dihydrocodeinone which~~  
7 ~~is also known as hydrocodone per one hundred milliliters or not more than~~  
8 ~~fifteen milligrams per dosage unit, with a fourfold or greater quantity~~  
9 ~~of an isoquinoline alkaloid of opium;~~

10 ~~(D) Not more than three hundred milligrams of dihydrocodeinone which~~  
11 ~~is also known as hydrocodone per one hundred milliliters or not more than~~  
12 ~~fifteen milligrams per dosage unit, with one or more active, nonnarcotic~~  
13 ~~ingredients in recognized therapeutic amounts;~~

14 (C E) Not more than one and eight-tenths grams of dihydrocodeine per  
15 one hundred milliliters or not more than ninety milligrams per dosage  
16 unit, with one or more active, nonnarcotic ingredients in recognized  
17 therapeutic amounts;

18 (D F) Not more than three hundred milligrams of ethylmorphine per  
19 one hundred milliliters or not more than fifteen milligrams per dosage  
20 unit, with one or more active, nonnarcotic ingredients in recognized  
21 therapeutic amounts;

22 (E G) Not more than five hundred milligrams of opium per one hundred  
23 milliliters or per one hundred grams, or not more than twenty-five  
24 milligrams per dosage unit, with one or more active, nonnarcotic  
25 ingredients in recognized therapeutic amounts; and

26 (E H) Not more than fifty milligrams of morphine per one hundred  
27 milliliters or per one hundred grams with one or more active, nonnarcotic  
28 ingredients in recognized therapeutic amounts; and

29 (2) Any material, compound, mixture, or preparation containing any  
30 of the following narcotic drug or its salts, as set forth below:

31 (A) Buprenorphine.

1 (d) Unless contained on the administration's list of exempt anabolic  
2 steroids as the list existed on January 1, 2014, any anabolic steroid,  
3 which shall include any material, compound, mixture, or preparation  
4 containing any quantity of the following substances, including its salts,  
5 isomers, and salts of isomers whenever the existence of such salts of  
6 isomers is possible within the specific chemical designation:

7 (1) 3-beta,17-dihydroxy-5a-androstane ~~Boldenone~~;

8 (2) 3-alpha,17-beta-dihydroxy-5a-androstane ~~Boldione~~;

9 (3) 5-alpha-androstan-3,17-dione ~~Chlorotestosterone~~ (4-  
10 ~~chlortestosterone~~);

11 (4) 1-androstenediol (3-beta,17-beta-dihydroxy-5-alpha-androst-1-  
12 ene) ~~Clostebol~~;

13 (5) 1-androstenediol (3-alpha,17-beta-dihydroxy-5-alpha-androst-1-  
14 ene) ~~Dehydrochloromethyltestosterone~~;

15 (6) 4-androstenediol (3-beta,17-beta-dihydroxy-androst-5-ene)  
16 ~~Desoxymethyltestosterone~~;

17 (7) 5-androstenediol (3-beta,17-beta-dihydroxy-androst-5-ene)  
18 ~~Dihydrotestosterone (4-dihydrotestosterone)~~;

19 (8) 1-androstenedione ([5-alpha]-androst-1-en-3,17-dione)  
20 ~~Drostanolone~~;

21 (9) 4-androstenedione (androst-4-en-3,17-dione) ~~Ethylestrenol~~;

22 (10) 5-androstenedione (androst-5-en-3,17-dione) ~~Fluoxymesterone~~;

23 (11) Bolasterone (7-alpha,17-alpha-dimethyl-17-beta-  
24 hydroxyandrost-4-en-3-one) ~~Formebolone (formebolone)~~;

25 (12) Boldenone (17-beta-hydroxyandrost-1,4-diene-3-one) ~~Mesterolone~~;

26 (13) Boldione (androsta-1,4-diene-3,17-3-one) ~~Methandienone~~;

27 (14) Calusterone (7-beta,17-alpha-dimethyl-17-beta-hydroxyandrost-4-  
28 en-3-one) ~~Methandranone~~;

29 (15) Clostebol (4-chloro-17-beta-hydroxyandrost-4-en-3-one)  
30 ~~Methandriol~~;

31 (16) Dehydrochloromethyltestosterone (4-chloro-17-beta-hydroxy-17-



- 1 alpha-methyl-androst-1,4-dien-3-one) Methandrostenolone;
- 2 (17) Desoxymethyltestosterone (17-alpha-methyl-5-alpha-androst-2-
- 3 en-17-beta-ol) (a.k.a. 'madol') Methenolone;
- 4 (18) Delta-1-Dihydrotestosterone (a.k.a. '1-testosterone')(17-beta-
- 5 hydroxy-5-alpha-androst-1-en-3-one) Methyltestosterone;
- 6 (19) 4-Dihydrotestosterone (17-beta-hydroxy-androstan-3-one)
- 7 Mibolerone;
- 8 (20) Drostanolone (17-beta-hydroxy-2-alpha-methyl-5-alpha-
- 9 androstan-3-one) Nandrolone;
- 10 (21) Ethylestrenol (17-alpha-ethyl-17-beta-hydroxyestr-4-ene)
- 11 Norethandrolone;
- 12 (22) Fluoxymesterone (9-fluoro-17-alpha-methyl-11-beta,17-beta-
- 13 dihydroxyandrost-4-en-3-one) Oxandrolone;
- 14 (23) Formebolone (formebolone); (2-formyl-17-alpha-methyl-11-alpha,
- 15 17-beta-dihydroxyandrost-1,4-dien-3-one) Oxymesterone;
- 16 (24) Furazabol (17-alpha-methyl-17-beta-hydroxyandrostan[2,3-c]-
- 17 furazan) Oxymetholone;
- 18 (25) 13-beta-ethyl-17-beta-hydroxygon-4-en-3-one Stanolone;
- 19 (26) 4-hydroxytestosterone (4,17-beta-dihydroxy-androst-4-en-3-one)
- 20 Stanozolol;
- 21 (27) 4-hydroxy-19-nortestosterone (4,17-beta-dihydroxy-estr-4-en-3-
- 22 one) Testolactone;
- 23 (28) Mestanolone (17-alpha-methyl-17-beta-hydroxy-5-androstan-3-one)
- 24 Testosterone;
- 25 (29) Mesterolone (17-alpha-methyl-17-beta-hydroxy-5-androstan-3-one)
- 26 Trenbolone;
- 27 (30) Methandienone (17-alpha-methyl-17-beta-hydroxyandrost-1,4-
- 28 dien-3-one); 19-nor-4,9(10)-androstadienedione; and
- 29 (31) Methandriol (17-alpha-methyl-3-beta,17-beta-dihydroxyandrost-5-
- 30 ene);
- 31 (32) Methasterone (2-alpha,17-alpha-dimethyl-5-alpha-androstan-17-

- 1 beta-ol-3-one);  
2 (33) Methenolone (1-methyl-17-beta-hydroxy-5-alpha-androst-1-en-3-  
3 one);  
4 (34) 17-alpha-methyl-3-beta,17-beta-dihydroxy-5a-androstane;  
5 (35) 17-alpha-methyl-3-alpha,17-beta-dihydroxy-5a-androstane;  
6 (36) 17-alpha-methyl-3-beta,17-beta-dihydroxyandrost-4-ene;  
7 (37) 17-alpha-methyl-4-hydroxynandrolone (17-alpha-methyl-4-  
8 hydroxy-17-beta-hydroxyestr-4-en-3-one);  
9 (38) Methyldienolone (17-alpha-methyl-17-beta-hydroxyestra-4,9(10)-  
10 dien-3-one);  
11 (39) Methyltrienolone (17-alpha-methyl-17-beta-hydroxyestra-4,9,11-  
12 trien-3-one);  
13 (40) Methyltestosterone (17-alpha-methyl-17-beta-hydroxyandrost-4-  
14 en-3-one);  
15 (41) Mibolerone (7-alpha,17-alpha-dimethyl-17-beta-hydroxyestr-4-  
16 en-3-one);  
17 (42) 17-alpha-methyl-delta-1-dihydrotestosterone (17-beta-  
18 hydroxy-17-alpha-methyl-5-alpha-androst-1-en-3-one) (a.k.a. '17-alpha-  
19 methyl-1-testosterone');  
20 (43) Nandrolone (17-beta-hydroxyestr-4-en-3-one);  
21 (44) 19-nor-4-androstenediol (3-beta, 17-beta-dihydroxyestr-4-ene);  
22 (45) 19-nor-4-androstenediol (3-alpha, 17-beta-dihydroxyestr-4-ene);  
23 (46) 19-nor-5-androstenediol (3-beta, 17-beta-dihydroxyestr-5-ene);  
24 (47) 19-nor-5-androstenediol (3-alpha, 17-beta-dihydroxyestr-5-ene);  
25 (48) 19-nor-4,9(10)-androstadienedione (estra-4,9(10)-diene-3,17-  
26 dione);  
27 (49) 19-nor-4-androstenedione (estr-4-en-3,17-dione);  
28 (50) 19-nor-5-androstenedione (estr-5-en-3,17-dione);  
29 (51) Norbolethone (13-beta, 17-alpha-diethyl-17-beta-hydroxygon-4-  
30 en-3-one);  
31 (52) Norclostebol (4-chloro-17-beta-hydroxyestr-4-en-3-one);

- 1           (53) Norethandrolone (17-alpha-ethyl-17-beta-hydroxyestr-4-en-3-  
2 one);
- 3           (54) Normethandrolone (17-alpha-methyl-17-beta-hydroxyestr-4-en-3-  
4 one);
- 5           (55) Oxandrolone (17-alpha-methyl-17-beta-hydroxy-2-oxa-[5-alpha]-  
6 androstan-3-one);
- 7           (56) Oxymesterone (17-alpha-methyl-4,17-beta-dihydroxyandrost-4-  
8 en-3-one);
- 9           (57) Oxymetholone (17-alpha-methyl-2-hydroxymethylene-17-beta-  
10 hydroxy-[5-alpha]-androstan-3-one);
- 11           (58) Prostanazol (17-beta-hydroxy-5-alpha-androstano[3,2-  
12 c]pyrazole);
- 13           (59) Stanozolol (17-alpha-methyl-17-beta-hydroxy-[5-alpha]-  
14 androst-2-eno[3,2-c]-pyrazole);
- 15           (60) Stenbolone (17-beta-hydroxy-2-methyl-[5-alpha]-androst-1-en-3-  
16 one);
- 17           (61) Testolactone (13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-  
18 oic acid lactone);
- 19           (62) Testosterone (17-beta-hydroxyandrost-4-en-3-one);
- 20           (63) Tetrahydrogestrinone (13-beta, 17-alpha-diethyl-17-beta-  
21 hydroxygon-4,9,11-trien-3-one);
- 22           (64) Trenbolone (17-beta-hydroxyestr-4,9,11-trien-3-one); and
- 23           (65 ±) Any salt, ester, or ether of a drug or substance described  
24 or listed in this subdivision if the salt, ester, or ether promotes  
25 muscle growth.
- 26           (e) Hallucinogenic substances known as:
- 27           (1) Dronabinol, synthetic, in sesame oil and encapsulated in a soft  
28 gelatin capsule in a drug product approved by the federal Food and Drug  
29 Administration. Some other names for dronabinol are (6aR-trans)-6a,  
30 7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo (b,d)pyran-1-ol or  
31 (-)-delta-9-(trans)-tetrahydrocannabinol.

1 Schedule IV

2 (a) Any material, compound, mixture, or preparation which contains  
3 any quantity of the following substances, including their salts, isomers,  
4 and salts of isomers whenever the existence of such salts, isomers, and  
5 salts of isomers is possible within the specific chemical designation:

6 (1) Barbital;

7 (2) Chloral betaine;

8 (3) Chloral hydrate;

9 (4) Chlordiazepoxide, but not including librax (chlordiazepoxide  
10 hydrochloride and clindinium bromide) or menrium (chlordiazepoxide and  
11 water soluble esterified estrogens);

12 (5) Clonazepam;

13 (6) Clorazepate;

14 (7) Diazepam;

15 (8) Ethchlorvynol;

16 (9) Ethinamate;

17 (10) Flurazepam;

18 (11) Mebutamate;

19 (12) Meprobamate;

20 (13) Methohexital;

21 (14) Methylphenobarbital;

22 (15) Oxazepam;

23 (16) Paraldehyde;

24 (17) Petrichloral;

25 (18) Phenobarbital;

26 (19) Prazepam;

27 (20) Alprazolam;

28 (21) Bromazepam;

29 (22) Camazepam;

30 (23) Clobazam;

31 (24) Clotiazepam;

- 1 (25) Cloxazolam;
- 2 (26) Delorazepam;
- 3 (27) Estazolam;
- 4 (28) Ethyl loflazepate;
- 5 (29) Fludiazepam;
- 6 (30) Flunitrazepam;
- 7 (31) Halazepam;
- 8 (32) Haloxazolam;
- 9 (33) Ketazolam;
- 10 (34) Loprazolam;
- 11 (35) Lorazepam;
- 12 (36) Lormetazepam;
- 13 (37) Medazepam;
- 14 (38) Nimetazepam;
- 15 (39) Nitrazepam;
- 16 (40) Nordiazepam;
- 17 (41) Oxazolam;
- 18 (42) Pinazepam;
- 19 (43) Temazepam;
- 20 (44) Tetrazepam;
- 21 (45) Triazolam;
- 22 (46) Midazolam;
- 23 (47) Quazepam;
- 24 (48) Zolpidem;
- 25 (49) Dichloralphenazone; ~~and~~
- 26 (50) Zaleplon; ~~and~~
- 27 (51) Zopiclone;
- 28 (52) Fospropofol;
- 29 (53) Alfaxalone;
- 30 (54) Suvorexant; and
- 31 (55) Carisoprodol.

1 (b) Any material, compound, mixture, or preparation which contains  
2 any quantity of the following substance, including its salts, isomers,  
3 whether optical, position, or geometric, and salts of such isomers,  
4 whenever the existence of such salts, isomers, and salts of isomers is  
5 possible: Fenfluramine.

6 (c) Unless specifically excepted or unless listed in another  
7 schedule, any material, compound, mixture, or preparation which contains  
8 any quantity of the following substances having a stimulant effect on the  
9 central nervous system, including their salts, isomers, whether optical,  
10 position, or geometric, and salts of such isomers whenever the existence  
11 of such salts, isomers, and salts of isomers is possible within the  
12 specific chemical designation:

- 13 (1) Diethylpropion;
- 14 (2) Phentermine;
- 15 (3) Pemoline, including organometallic complexes and chelates  
16 thereof;
- 17 (4) Mazindol;
- 18 (5) Pipradrol;
- 19 (6) SPA, ((-)-1-dimethylamino- 1,2-diphenylethane);
- 20 (7) Cathine. Another name for cathine is ((+)-norpseudoephedrine);
- 21 (8) Fencamfamin;
- 22 (9) Fenproporex;
- 23 (10) Mefenorex;
- 24 (11) Modafinil; and
- 25 (12) Sibutramine.

26 (d) Unless specifically excepted or unless listed in another  
27 schedule, any material, compound, mixture, or preparation which contains  
28 any quantity of the following narcotic drugs, or their salts or isomers  
29 calculated as the free anhydrous base or alkaloid, in limited quantities  
30 as set forth below:

- 31 (1) Propoxyphene in manufactured dosage forms; ~~and~~

1 (2) Not more than one milligram of difenoxin and not less than  
2 twenty-five micrograms of atropine sulfate per dosage unit; and -

3 (3) 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol, its  
4 salts, optical and geometric isomers and salts of these isomers to  
5 include: Tramadol.

6 (e) Unless specifically excepted or unless listed in another  
7 schedule, any material, compound, mixture, or preparation which contains  
8 any quantity of the following substance, including its salts:

9 (1) Pentazocine; and -

10 (2) Butorphanol (including its optical isomers).

11 (f) Any material, compound, mixture, or preparation which contains  
12 any quantity of the following substances, including its salts, isomers,  
13 and salts of such isomers, whenever the existence of such salts, isomers,  
14 and salts of isomers is possible: Lorcaserin ~~Unless specifically excepted~~  
15 ~~or unless listed in another schedule, any material, compound, mixture, or~~  
16 ~~preparation which contains any quantity of the following substance,~~  
17 ~~including its salts, isomers, and salts of such isomers: Butorphanol.~~

18 ~~(g) Unless specifically excepted or unless listed in another~~  
19 ~~schedule, any material, compound, mixture, or preparation which contains~~  
20 ~~any quantity of the following substance, including its salts, isomers,~~  
21 ~~and salts of such isomers: Carisoprodol.~~

22 (g ~~h~~)(1) Unless specifically excepted or unless listed in another  
23 schedule, any material, compound, mixture, or preparation which contains  
24 any quantity of the following substance, including its salts, optical  
25 isomers, and salts of such optical isomers: Ephedrine.

26 (2) The following drug products containing ephedrine, its salts,  
27 optical isomers, and salts of such optical isomers, are excepted from  
28 subdivision (g)(1) ~~(h)(1)~~ of Schedule IV if they (A) are stored behind a  
29 counter, in an area not accessible to customers, or in a locked case so  
30 that a customer needs assistance from an employee to access the drug  
31 product; (B) are sold by a person, eighteen years of age or older, in the

1 course of his or her employment to a customer eighteen years of age or  
2 older with the following restrictions: No customer shall be allowed to  
3 purchase, receive, or otherwise acquire more than three and six-tenths  
4 grams of ephedrine base during a twenty-four-hour period; no customer  
5 shall purchase, receive, or otherwise acquire more than nine grams of  
6 ephedrine base during a thirty-day period; and the customer shall display  
7 a valid driver's or operator's license, a Nebraska state identification  
8 card, a military identification card, an alien registration card, or a  
9 passport as proof of identification; (C) are labeled and marketed in a  
10 manner consistent with the pertinent OTC Tentative Final or Final  
11 Monograph; (D) are manufactured and distributed for legitimate medicinal  
12 use in a manner that reduces or eliminates the likelihood of abuse; and  
13 (E) are not marketed, advertised, or represented in any manner for the  
14 indication of stimulation, mental alertness, euphoria, ecstasy, a buzz or  
15 high, heightened sexual performance, or increased muscle mass:

16 (i) Primatene Tablets; and

17 (ii) Bronkaid Dual Action Caplets.

18 Schedule V

19 (a) Any compound, mixture, or preparation containing any of the  
20 following limited quantities of narcotic drugs or salts calculated as the  
21 free anhydrous base or alkaloid, which shall include one or more  
22 nonnarcotic active medicinal ingredients in sufficient proportion to  
23 confer upon the compound, mixture, or preparation valuable medicinal  
24 qualities other than those possessed by the narcotic drug alone:

25 (1) Not more than two hundred milligrams of codeine per one hundred  
26 milliliters or per one hundred grams;

27 (2) Not more than one hundred milligrams of dihydrocodeine per one  
28 hundred milliliters or per one hundred grams;

29 (3) Not more than one hundred milligrams of ethylmorphine per one  
30 hundred milliliters or per one hundred grams;

31 (4) Not more than two and five-tenths milligrams of diphenoxylate



1 and not less than twenty-five micrograms of atropine sulfate per dosage  
2 unit;

3 (5) Not more than one hundred milligrams of opium per one hundred  
4 milliliters or per one hundred grams; and

5 (6) Not more than five-tenths milligram of difenoxin and not less  
6 than twenty-five micrograms of atropine sulfate per dosage unit.

7 (b) Unless specifically exempted or excluded or unless listed in  
8 another schedule, any material, compound, mixture, or preparation which  
9 contains any quantity of the following substances having a stimulant  
10 effect on the central nervous system, including its salts, isomers, and  
11 salts of isomers: Pyrovalerone.

12 (c) Unless specifically exempted or excluded or unless listed in  
13 another schedule, any material, compound, mixture, or preparation which  
14 contains any quantity of the following substances having a depressant  
15 effect on the central nervous system, including its salts, isomers, and  
16 salts of isomers:

17 (1) Ezogabine (N-(2-amino-4-(4-fluorobenzylamino)-phenyl)-carbamic  
18 acid ethyl ester);

19 (2) Lacosamide ((R)-2-acetoamido-N-benzyl-3-methoxy-propionamide);  
20 and

21 (3) Pregabalin ((S)-3-(aminomethyl)-5-methylhexanoic acid).

22 Sec. 11. (1) A health professional who is authorized to prescribe  
23 or dispense naloxone, if acting with reasonable care, may prescribe,  
24 administer, or dispense naloxone to any of the following persons without  
25 being subject to administrative action or criminal prosecution;

26 (a) A person who is apparently experiencing or who is likely to  
27 experience an opioid-related overdose; or

28 (b) A family member, friend, or other person in a position to assist  
29 a person who is apparently experiencing or who is likely to experience an  
30 opioid-related overdose.

31 (2) A family member, friend, or other person who is in a position to

1 assist a person who is apparently experiencing or who is likely to  
2 experience an opioid-related overdose, other than an emergency responder  
3 or peace officer, is not subject to actions under the Uniform  
4 Credentialing Act, administrative action, or criminal prosecution if the  
5 person, acting in good faith, obtains naloxone from a health professional  
6 or a prescription for naloxone from a health professional and administers  
7 the naloxone obtained from the health professional or acquired pursuant  
8 to the prescription to a person who is apparently experiencing an opioid-  
9 related overdose.

10 (3) An emergency responder is not subject to administrative action  
11 or criminal prosecution if the emergency responder, acting in good faith,  
12 obtains naloxone from the emergency responder's emergency medical service  
13 organization and administers the naloxone to a person who is apparently  
14 experiencing an opioid-related overdose.

15 (4) A peace officer is not subject to administrative action or  
16 criminal prosecution if the peace officer, acting in good faith, obtains  
17 naloxone from the peace officer's law enforcement agency and administers  
18 the naloxone to a person who is apparently experiencing an opioid-related  
19 overdose.

20 (5) For purposes of this section:

21 (a) Administer has the same meaning as in section 38-2806;

22 (b) Dispense has the same meaning as in section 38-2817;

23 (c) Emergency responder means first responder, emergency medical  
24 technician, emergency medical technician-intermediate, or emergency  
25 medical technician-paramedic licensed under the Emergency Medical  
26 Services Practice Act;

27 (d) Health professional means a physician, physician assistant,  
28 nurse practitioner, or pharmacist licensed under the Uniform  
29 Credentialing Act;

30 (e) Law enforcement agency means police department, a town marshal,  
31 the office of sheriff, or the Nebraska State Patrol;

1           (f) Naloxone means naloxone hydrochloride; and

2           (g) Peace officer has the same meaning as in section 49-801.

3           2. On page 1, line 6; and page 9, line 1, strike "4 to 10" and all  
4 amendments thereto and insert "5 to 11".

5           3. On page 3, line 15; page 9, lines 3 and 18; and page 11, line 28,  
6 strike "4 to 10" and all amendments thereto and insert "5 to 10".

7           4. On page 9, line 31; and page 12, lines 3 and 7, strike "6" and  
8 insert "7".

9           5. On page 12, lines 12 and 16 and 17 strike "4 to 11" and all  
10 amendments thereto and insert "5 to 10".

11          6. On page 13, line 10, strike "4 to 10" and all amendments thereto  
12 and insert "5 to 10".

13          7. Renumber the remaining sections and correct the repealer  
14 accordingly.